Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Innovstone Therapeutics Limited has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners, though they are both located within 1 distinct art unit. This indicates that while the company is interacting with different individuals, the subject matter remains focused within a specific regulatory group at the patent office.
The busiest examiner for this portfolio is RZECZYCKI, PHILLIP MATTHEW, who is responsible for 1 pending action. Since there are 2 pending office actions in total, the workload is split among the 2 distinct examiners. The concentration in 1 distinct art unit suggests that the legal strategy can remain consistent even when dealing with different examiners like RZECZYCKI, PHILLIP MATTHEW. Practitioners should leverage the commonality of the 1 distinct art unit to streamline their arguments, even as they address the specific feedback from the 2 distinct examiners involved in these cases. This approach ensures that the 2 pending office actions are prosecuted with a unified technical focus.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720535 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WELLS, LAUREN QUINLAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19559874 | Substituted 2-(Pyrrolidine-3-yl)acetic Acid Derivative, Preparation Method and Use Thereof | RZECZYCKI, PHILLIP MATTHEW | — |
| 18720535 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WELLS, LAUREN QUINLAN | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19559874 | Substituted 2-(Pyrrolidine-3-yl)acetic Acid Derivative, Preparation Method and Use Thereof | RZECZYCKI, PHILLIP MATTHEW | 1625 | DP | Final Rejection | — | Pending | Mar 06, 2026 |
| 18720535 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WELLS, LAUREN QUINLAN | — | §102§103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial